Quick Answer
BIODESIX INC reported Cash and Equivalents of $18.99 million for fiscal year 2025.
BIODESIX INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $18.99M | -27.7% |
| 2024 | $26.25M | -0.1% |
| 2023 | $26.28M | -39.0% |
| 2022 | $43.09M | +31.7% |
| 2021 | $32.71M | -47.3% |
| 2020 | $62.13M | +1075.3% |
| 2019 | $5.29M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $16.60M | -47.1% | -19.9% |
| June 30, 2025 | $20.73M | -50.9% | +17.8% |
| March 31, 2025 | $17.60M | +53.2% | -32.9% |
| December 31, 2024 | $26.25M | -0.1% | -16.4% |
| September 30, 2024 | $31.41M | +58.3% | -25.6% |
| June 30, 2024 | $42.22M | +142.5% | +267.4% |
| March 31, 2024 | $11.49M | -54.5% | -56.3% |
| December 31, 2023 | $26.28M | -39.0% | +32.5% |
- BIODESIX INC showed a decrease of -27.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, BIODESIX INC’s cash and equivalents has grown by 259.2% (from $5.29 million to $18.99 million).
- The most recent figure is from BIODESIX INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: